Jim Simons
DSGN icon

Jim Simons’s Design Therapeutics DSGN Stock Holding History

Jim Simons’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.34M Buy
408,200
+121,100
+42% +$1.23M 0.01% 1458
2025
Q4 		$2.69M Buy
287,100
+12,800
+5% +$100K ﹤0.01% 1685
2025
Q3 		$2.07M Buy
274,300
+6,500
+2% +$32.6K ﹤0.01% 2049
2025
Q2 		$902K Buy
267,800
+2,800
+1% +$10.5K ﹤0.01% 2572
2025
Q1 		$1.02M Buy
265,000
+11,500
+5% +$54.9K ﹤0.01% 2416
2024
Q4 		$1.56M Sell
253,500
-20,500
-7% -$119K ﹤0.01% 2206
2024
Q3 		$1.47M Sell
274,000
-110,075
-29% -$518K ﹤0.01% 2220
2024
Q2 		$1.29M Sell
384,075
-69,325
-15% -$270K ﹤0.01% 2176
2024
Q1 		$1.83M Sell
453,400
-195,400
-30% -$522K ﹤0.01% 2090
2023
Q4 		$1.72M Buy
648,800
+484,600
+295% +$1.11M ﹤0.01% 2048
2023
Q3 		$388K Buy
164,200
+69,092
+73% +$322K ﹤0.01% 2829
2023
Q2 		$599K Sell
95,108
-6,643
-7% -$40.7K ﹤0.01% 2765
2023
Q1 		$587K Buy
+101,751
New +$761K ﹤0.01% 2794

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jim Simons's DSGN Position: Q1 2026 in Review

Jim Simons increased its Design Therapeutics (DSGN) stake by 42% in Q1 2026, buying an estimated $1.23M and bringing the position to 408,200 shares worth $4.34M. The position accounts for 0.01% of the portfolio, ranked #1458.

Jim Simons first reported a position in DSGN in Q1 2023 and has held it in 13 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Jim Simons held 408,200 shares of Design Therapeutics worth $4.34M as of Q1 2026.
  • Jim Simons bought 121,100 Design Therapeutics shares in Q1 2026, an estimated $1.23M.
  • Design Therapeutics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1458 holding.
  • Jim Simons first reported a position in Design Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.